Gene co-expression modules integrated with immunoscore predicts survival of non-small cell lung cancer.

[1]  Ying Cheng,et al.  Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients , 2019, Nature Communications.

[2]  Olga Tanaseichuk,et al.  Metascape provides a biologist-oriented resource for the analysis of systems-level datasets , 2019, Nature Communications.

[3]  N. Beerenwinkel,et al.  Neutrophils escort circulating tumour cells to enable cell cycle progression , 2019, Nature.

[4]  D. Planchard,et al.  Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC , 2018, The New England journal of medicine.

[5]  P. Carmeliet,et al.  Phenotype molding of stromal cells in the lung tumor microenvironment , 2018, Nature Medicine.

[6]  Young Uk Kim,et al.  Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome , 2018, Clinical Cancer Research.

[7]  W. Liao,et al.  Gene expression profiles for a prognostic immunoscore in gastric cancer , 2018, The British journal of surgery.

[8]  James A. Eddy,et al.  The Immune Landscape of Cancer. , 2018, Immunity.

[9]  J. Szustakowski,et al.  Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden , 2018, The New England journal of medicine.

[10]  V. Gebski,et al.  Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis , 2017, JAMA oncology.

[11]  Angela E. Leek,et al.  Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution , 2017, Cell.

[12]  E. Felip,et al.  Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Harini Veeraraghavan,et al.  Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient , 2017, Cell.

[14]  Laurence Zitvogel,et al.  The immune contexture in cancer prognosis and treatment , 2017, Nature Reviews Clinical Oncology.

[15]  P. Jänne,et al.  Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  E. Eruslanov.  Phenotype and function of tumor-associated neutrophils and their subsets in early-stage human lung cancer , 2017, Cancer Immunology, Immunotherapy.

[17]  Ting Wu,et al.  Tumor microenvironment and therapeutic response. , 2017, Cancer letters.

[18]  N. McGranahan,et al.  Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future , 2017, Cell.

[19]  I. Mellman,et al.  Elements of cancer immunity and the cancer–immune set point , 2017, Nature.

[20]  Carlos Caldas,et al.  Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study , 2016, PLoS medicine.

[21]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[22]  Abhishek S. Rao,et al.  Origin and Role of a Subset of Tumor-Associated Neutrophils with Antigen-Presenting Cell Features in Early-Stage Human Lung Cancer. , 2016, Cancer cell.

[23]  Pornpimol Charoentong,et al.  Computational genomics tools for dissecting tumour–immune cell interactions , 2016, Nature Reviews Genetics.

[24]  K. E. Visser,et al.  Neutrophils in cancer: neutral no more , 2016, Nature Reviews Cancer.

[25]  S. Digumarthy,et al.  EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis , 2016, Clinical Cancer Research.

[26]  Daniel S. Chen,et al.  Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  Nicolai J. Birkbak,et al.  Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade , 2016, Science.

[28]  M. Colombo,et al.  The Role of Mast Cells in Molding the Tumor Microenvironment , 2015, Cancer Microenvironment.

[29]  Ash A. Alizadeh,et al.  Abstract PR09: The prognostic landscape of genes and infiltrating immune cells across human cancers , 2015 .

[30]  Antoni Ribas,et al.  Classifying Cancers Based on T-cell Infiltration and PD-L1. , 2015, Cancer research.

[31]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.

[32]  B. Molon,et al.  Spotlights on immunological effects of reactive nitrogen species: When inflammation says nitric oxide. , 2015, World journal of experimental medicine.

[33]  F. Cappuzzo,et al.  Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. , 2015, The Lancet. Oncology.

[34]  R. Herbst,et al.  Objective measurement and clinical significance of TILs in non-small cell lung cancer. , 2015, Journal of the National Cancer Institute.

[35]  M. Merad,et al.  The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome. , 2015, American journal of respiratory and critical care medicine.

[36]  S. Shen-Orr,et al.  Computational deconvolution: extracting cell type-specific information from heterogeneous samples. , 2013, Current opinion in immunology.

[37]  Hugues Bersini,et al.  Batch effect removal methods for microarray gene expression data integration: a survey , 2013, Briefings Bioinform..

[38]  K. Okkenhaug.  Signaling by the phosphoinositide 3-kinase family in immune cells. , 2013, Annual review of immunology.

[39]  P. Kubes,et al.  Neutrophil recruitment and function in health and inflammation , 2013, Nature Reviews Immunology.

[40]  P. Hofman,et al.  Predictive clinical outcome of the intratumoral CD66b‐positive neutrophil‐to‐CD8‐positive T‐cell ratio in patients with resectable nonsmall cell lung cancer , 2012, Cancer.

[41]  Alberto Mantovani,et al.  Neutrophils in the activation and regulation of innate and adaptive immunity , 2011, Nature Reviews Immunology.

[42]  V. Cerundolo,et al.  Invariant NKT cells modulate the suppressive activity of Serum Amyloid A-differentiated IL-10-secreting neutrophils , 2010, Nature immunology.

[43]  T. Strutt,et al.  The potential of CD4 T‐cell memory , 2010, Immunology.

[44]  S. Horvath,et al.  WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.

[45]  T. Whiteside.  The tumor microenvironment and its role in promoting tumor growth , 2008, Oncogene.

[46]  H. Turner,et al.  Exposure to tobacco-derived materials induces overproduction of secreted proteinases in mast cells. , 2005, Toxicology and applied pharmacology.

[47]  B. Stockinger,et al.  Tumor and CD4 T-cell interactions: tumor escape as result of reciprocal inactivation. , 2003, Blood.

[48]  R. Tibshirani.  The lasso method for variable selection in the Cox model. , 1997, Statistics in medicine.

[49]  Ash A. Alizadeh,et al.  SUPPLEMENTARY NOTE , 1879, Botanical Gazette.